Abstract
Introduction and Magnitude of the Disease
Lymphatic filariasis is a vector‑borne neglected tropical disease
of parasitic origin and is a major public health concern.[1] In fact,
the available global estimates suggest that more than 35 million
people are suffering from the chronic manifestations (such as
lymphedema, disability, and hydrocele) of the disease.[1,2] In
addition, currently in excess of 850 million people residing in
52 endemic nations are in need of prophylactic chemotherapy,
while close to 500 million people no longer need the same
owing to the implementation of the recommended strategies.[1,2]
However, the disease accounts for the loss of millions of dollars
due to reduced productivity and even cast a major burden on
the health system.[1]
Lymphatic filariasis is a vector‑borne neglected tropical disease
of parasitic origin and is a major public health concern.[1] In fact,
the available global estimates suggest that more than 35 million
people are suffering from the chronic manifestations (such as
lymphedema, disability, and hydrocele) of the disease.[1,2] In
addition, currently in excess of 850 million people residing in
52 endemic nations are in need of prophylactic chemotherapy,
while close to 500 million people no longer need the same
owing to the implementation of the recommended strategies.[1,2]
However, the disease accounts for the loss of millions of dollars
due to reduced productivity and even cast a major burden on
the health system.[1]